ProfileGDS4814 / ILMN_1713272
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 1% 11% 9% 5% 34% 15% 1% 1% 4% 1% 18% 10% 23% 7% 4% 2% 6% 8% 7% 4% 9% 27% 33% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)35.79871
GSM780708Untreated after 4 days (C2_1)41.347111
GSM780709Untreated after 4 days (C3_1)40.71869
GSM780719Untreated after 4 days (C1_2)39.20495
GSM780720Untreated after 4 days (C2_2)46.482934
GSM780721Untreated after 4 days (C3_2)42.437915
GSM780710Trastuzumab treated after 4 days (T1_1)36.42681
GSM780711Trastuzumab treated after 4 days (T2_1)36.94081
GSM780712Trastuzumab treated after 4 days (T3_1)39.15674
GSM780722Trastuzumab treated after 4 days (T1_2)33.34451
GSM780723Trastuzumab treated after 4 days (T2_2)43.024718
GSM780724Trastuzumab treated after 4 days (T3_2)41.248510
GSM780713Pertuzumab treated after 4 days (P1_1)44.231823
GSM780714Pertuzumab treated after 4 days (P2_1)40.27027
GSM780715Pertuzumab treated after 4 days (P3_1)38.8424
GSM780725Pertuzumab treated after 4 days (P1_2)37.17942
GSM780726Pertuzumab treated after 4 days (P2_2)39.9276
GSM780727Pertuzumab treated after 4 days (P3_2)40.50398
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)40.27547
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)38.69484
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)40.75799
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)44.898527
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)46.26233